# FDA approves Moderna's mRNA flu shot after turbulent review

The FDA has approved Moderna's mRNA-based influenza vaccine, marking the second mRNA vaccine authorized for use after its COVID-19 shot. The approval follows a review process that included setbacks and reconsideration of trial data. This decision expands mRNA technology to seasonal flu prevention, offering a potentially faster and more adaptable vaccine platform.

**Importance:** 4/5

## Sources

### Technology
- [Ars Technica](https://arstechnica.com/health/2026/08/modernas-mrna-flu-shot-earns-fda-approval-after-rollercoaster-review/) — Thu, 06 Aug 2026 16:31:06 +0000